Another study showed that alectinib had significantly higher PFS (68.4% vs 48.7%) and ORR (82% vs 75.5%) over 12 months, in combination with lower toxicity (41% vs 50%) than crizotinib. These findings suggest that alectinib is solid choice to be used in first-line treatment for ALK-positive NSCLC patients (Camidge et al. 2019; McKeage 2015). The gene discussed is ALK; the disease is non-small cell lung carcinoma.